Foreign Corrupt Practices Act

Companies involved in cross-border transactions face numerous regulatory hurdles relating to the export and re-export of sensitive goods and technologies; investments and other dealings having national security implications; and relationships with persons and entities that may be governed by U.S. economic sanctions, anti-money laundering and anti-corruption laws.

Whistleblowers and the U.S. Department of Justice use the False Claims Act (FCA) to extract damages and civil penalties, which pose a significant threat to many corporations.

State attorneys general are conducting investigations and asserting claims under state laws modeled around the federal FCA, and more qui tam actions are being filed each year as the opportunity for significant whistleblower monetary awards increases.

Our FCA attorneys represent companies and their officers, directors, and employees in complex criminal fraud investigations, internal investigations, and civil and qui tam litigation . We have handled cases and investigations in numerous industries, including government contract, health care, pharmaceuticals and life sciences.

When a company is faced with a securities class action or shareholder derivative litigation, they need a partner who understands what is at stake and can think outside the box to achieve resolution. Goodwin’s deep experience, creative thinking and tenacity has led to our involvement in precedent-setting securities cases in courts across the country. The results we achieve are best of breed and have helped shape the law nationally, including outright dismissals of billions of dollars in putative class action and shareholder derivative claims. Our cases range from defending high tech and biotech companies in class action securities fraud litigation brought following restatements of earnings or the release of bad business news, to resolving shareholder derivative challenges, to multibillion dollar mergers and acquisitions.